Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00587223

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Epidermolysis Bullosa Dystrophica Clinical Trial

Official title:
A Prospective, Multicenter, Within Subject Controlled Study to Evaluate the Effect of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa

Clinical Trial Summary

The purpose of this study is to evaluate the use of Apligraf for the treatment of nonhealing wounds in subjects with dystrophic or junctional epidermolysis bullosa. Apligraf will be evaluated for efficacy and safety compared to a conventional nonadherent dressing. A matched-pair design will be used to evaluate Apligraf treatment versus conventional treatment in 68 study pairs.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00587223
Study type Interventional
Source Organogenesis
Contact
Status Terminated
Phase Phase 3
Start date December 2007
Completion date December 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT01263379 - Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa Phase 1/Phase 2
Completed NCT01716169 - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care N/A
Completed NCT00951964 - Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) Phase 2
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Recruiting NCT01019148 - Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Completed NCT03241628 - Proof of Concept Study for a Dressing Glove N/A
Not yet recruiting NCT05390073 - Growth Hormone in EB
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Not yet recruiting NCT06177353 - Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
Recruiting NCT06007235 - CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa N/A
Active, not recruiting NCT05843994 - Artificial Intelligence Patient App for RDEB SCCs
Active, not recruiting NCT05033574 - The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Completed NCT04908215 - INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Phase 2
Active, not recruiting NCT04171661 - Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa Early Phase 1
Terminated NCT00533572 - Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer N/A
Completed NCT00904163 - Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa N/A
Recruiting NCT03786237 - Rigosertib for RDEB-SCC Phase 1/Phase 2